Modus Therapeutics AB
https://www.modustx.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Modus Therapeutics AB
Revamped Modus Switches To Sepsis, Septic Shock For Sevuparin
After disappointment in sickle cell anemia, Modus Therapeutics will now develop its lead asset sevuparin as a treatment for sepsis and septic shock and plans a public listing in Sweden to fund the new strategy, its CEO tells Scrip.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Dilaforette AB
- Karolinska Development AB
- Modus Therapeutics AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Modus Therapeutics AB
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice